Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS.

J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185.

PMID:
30371800
2.

The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth.

Bowers LW, Lineberger CG, Ford NA, Rossi EL, Punjala A, Camp KK, Kimler BK, Fabian CJ, Hursting SD.

Breast Cancer Res Treat. 2018 Oct 26. doi: 10.1007/s10549-018-5021-6. [Epub ahead of print]

PMID:
30367332
3.

The Conundrum of Omega-3 Fatty Acids in Cancer Prevention Studies: Which One? How Much? What Biomarkers?

Fabian CJ, Kimler BF.

Cancer Prev Res (Phila). 2018 Apr;11(4):187-190. doi: 10.1158/1940-6207.CAPR-18-0061. Epub 2018 Mar 20.

PMID:
29559515
4.

Cognitive functioning and quality of life following chemotherapy in pre- and peri-menopausal women with breast cancer.

Klemp JR, Myers JS, Fabian CJ, Kimler BF, Khan QJ, Sereika SM, Stanton AL.

Support Care Cancer. 2018 Feb;26(2):575-583. doi: 10.1007/s00520-017-3869-3. Epub 2017 Aug 28.

5.

Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.

Khan QJ, Kimler BF, Reddy PS, Sharma P, Klemp JR, Nydegger JL, Yeh HW, Fabian CJ.

Breast Cancer Res Treat. 2017 Nov;166(2):491-500. doi: 10.1007/s10549-017-4429-8. Epub 2017 Aug 2.

PMID:
28770449
6.

An empirically derived dietary pattern associated with breast cancer risk is validated in a nested case-control cohort from a randomized primary prevention trial.

Hidaka BH, Kimler BF, Fabian CJ, Carlson SE.

Clin Nutr ESPEN. 2017 Feb;17:8-17. doi: 10.1016/j.clnesp.2016.10.008. Epub 2016 Nov 23.

PMID:
28361752
7.

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T, Brewster WR, O'Malley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips KA, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, Lu KH.

Clin Cancer Res. 2017 Jul 15;23(14):3628-3637. doi: 10.1158/1078-0432.CCR-15-2750. Epub 2017 Jan 31.

8.

Dietary Associations with a Breast Cancer Risk Biomarker Depend on Menopause Status.

Hidaka BH, Carlson SE, Kimler BF, Fabian CJ.

Nutr Cancer. 2016 Oct;68(7):1115-22. doi: 10.1080/01635581.2016.1208255. Epub 2016 Aug 11.

PMID:
27618149
9.

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M.

Clin Cancer Res. 2017 Feb 1;23(3):649-657. doi: 10.1158/1078-0432.CCR-16-0162. Epub 2016 Jun 14.

10.

Incorporating Biomarkers in Studies of Chemoprevention.

Fabian CJ, Kimler BF.

Adv Exp Med Biol. 2016;882:69-94. doi: 10.1007/978-3-319-22909-6_3. Review.

PMID:
26987531
11.

Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group.

Fabian CJ, Meyskens FL Jr, Bajorin DF, George TJ Jr, Jeter JM, Khan S, Tyne CA, William WN Jr.

J Clin Oncol. 2016 Jan 10;34(2):186-93. doi: 10.1200/JCO.2015.63.5979. Epub 2015 Nov 2.

12.

Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women.

Fabian CJ, Kimler BF, Phillips TA, Box JA, Kreutzjans AL, Carlson SE, Hidaka BH, Metheny T, Zalles CM, Mills GB, Powers KR, Sullivan DK, Petroff BK, Hensing WL, Fridley BL, Hursting SD.

Cancer Prev Res (Phila). 2015 Oct;8(10):912-21. doi: 10.1158/1940-6207.CAPR-14-0335.

13.

Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.

Fabian CJ, Kimler BF, Zalles CM, Phillips TA, Metheny T, Petroff BK, Havighurst TC, Kim K, Bailey HH, Heckman-Stoddard BM.

Cancer Prev Res (Phila). 2015 Dec;8(12):1146-55. doi: 10.1158/1940-6207.CAPR-15-0109. Epub 2015 Sep 21.

14.

Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.

Fabian CJ, Kimler BF, Phillips TA, Nydegger JL, Kreutzjans AL, Carlson SE, Hidaka BH, Metheny T, Zalles CM, Mills GB, Powers KR, Sullivan DK, Petroff BK, Hensing WL, Fridley BL, Hursting SD.

Cancer Prev Res (Phila). 2015 Oct;8(10):922-31. doi: 10.1158/1940-6207.CAPR-14-0336. Epub 2015 Aug 14.

15.

Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer.

Ford NA, Rossi EL, Barnett K, Yang P, Bowers LW, Hidaka BH, Kimler BF, Carlson SE, Shureiqi I, deGraffenried LA, Fabian CJ, Hursting SD.

Cancer Prev Res (Phila). 2015 Sep;8(9):796-806. doi: 10.1158/1940-6207.CAPR-15-0018. Epub 2015 Jun 22.

16.

Effects of Flaxseed Lignan Secoisolariciresinol Diglucosideon Preneoplastic Biomarkers of Cancer Progression in a Model of Simultaneous Breast and Ovarian Cancer Development.

Delman DM, Fabian CJ, Kimler BF, Yeh H, Petroff BK.

Nutr Cancer. 2015;67(5):857-64. doi: 10.1080/01635581.2015.1042549. Epub 2015 May 26.

17.

Omega-3 fatty acids for breast cancer prevention and survivorship.

Fabian CJ, Kimler BF, Hursting SD.

Breast Cancer Res. 2015 May 4;17:62. doi: 10.1186/s13058-015-0571-6. Review.

18.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators.

N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204.

19.

Omega-3 and omega-6 Fatty acids in blood and breast tissue of high-risk women and association with atypical cytomorphology.

Hidaka BH, Li S, Harvey KE, Carlson SE, Sullivan DK, Kimler BF, Zalles CM, Fabian CJ.

Cancer Prev Res (Phila). 2015 May;8(5):359-64. doi: 10.1158/1940-6207.CAPR-14-0351. Epub 2015 Feb 23.

20.

American Society of Clinical Oncology position statement on obesity and cancer.

Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, Fabian CJ, Gucalp A, Hershman DL, Hudson MM, Jones LW, Kakarala M, Ness KK, Merrill JK, Wollins DS, Hudis CA.

J Clin Oncol. 2014 Nov 1;32(31):3568-74. doi: 10.1200/JCO.2014.58.4680. Epub 2014 Oct 1.

21.

Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer.

Connor CS, Kimler BF, Mammen JM, McGinness MK, Wagner JL, Alsop SM, Ward C, Fabian CJ, Khan QJ, Sharma P.

J Surg Oncol. 2015 Feb;111(2):198-202. doi: 10.1002/jso.23790. Epub 2014 Sep 29.

PMID:
25266871
22.

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.

Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, Wagner JL, Ward C, Ranallo L, Knight CJ, Stecklein SR, Jensen RA, Fabian CJ, Godwin AK.

Breast Cancer Res Treat. 2014 Jun;145(3):707-14. doi: 10.1007/s10549-014-2980-0. Epub 2014 May 7.

23.

Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.

Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Alés-Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H.

J Clin Oncol. 2014 May 10;32(14):1427-36. doi: 10.1200/JCO.2013.51.2483. Epub 2014 Apr 7.

24.

Future directions for postdoctoral training in cancer prevention: insights from a panel of experts.

Nelson DE, Faupel-Badger J, Phillips S, Belcher B, Chang S, Abrams DB, Kramer BS, White MC, O'Malley M, Varanasi AP, Fabian CJ, Wiest JS, Colditz GA, Hall K, Shields PG, Weitzel JN.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):679-83. doi: 10.1158/1055-9965.EPI-13-1209. Epub 2014 Mar 6.

25.

Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10 % weight loss in postmenopausal women.

Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, Petroff BK, Phillips TA, Metheny T, Aversman S, Yeh HW, Zalles CM, Mills GB, Hursting SD.

Breast Cancer Res Treat. 2013 Nov;142(1):119-32. doi: 10.1007/s10549-013-2730-8. Epub 2013 Oct 19.

26.

Marine-derived omega-3 fatty acids: fishing for clues for cancer prevention.

Fabian CJ, Kimler BF.

Am Soc Clin Oncol Educ Book. 2013:97-101. doi: 10.1200/EdBook_AM.2013.33.97.

27.

Assessment of RNA in human breast tissue sampled by random periareolar fine needle aspiration and ductal lavage and processed as fixed or frozen specimens.

Phillips TA, Fabian CJ, Kimler BF, Petroff BK.

Reprod Biol. 2013 Mar;13(1):75-81. doi: 10.1016/j.repbio.2013.01.179. Epub 2013 Feb 19.

PMID:
23522074
28.

A prospective model of care for breast cancer rehabilitation: bone health and arthralgias.

Winters-Stone KM, Schwartz AL, Hayes SC, Fabian CJ, Campbell KL.

Cancer. 2012 Apr 15;118(8 Suppl):2288-99. doi: 10.1002/cncr.27465. Review.

29.

Simplifying the energy balance message for breast cancer prevention.

Fabian CJ.

Cancer Prev Res (Phila). 2012 Apr;5(4):511-4. doi: 10.1158/1940-6207.CAPR-12-0088.

30.

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.

Powles TJ, Diem SJ, Fabian CJ, Neven P, Wickerham DL, Cox DA, Muram D, Agnusdei D, Dowsett SA, Amewou-Atisso M, Cummings SR.

Breast Cancer Res Treat. 2012 Jul;134(1):299-306. doi: 10.1007/s10549-012-2041-5. Epub 2012 Apr 8.

PMID:
22484799
31.

Outcomes of a weight loss intervention among rural breast cancer survivors.

Befort CA, Klemp JR, Austin HL, Perri MG, Schmitz KH, Sullivan DK, Fabian CJ.

Breast Cancer Res Treat. 2012 Apr;132(2):631-9. doi: 10.1007/s10549-011-1922-3. Epub 2011 Dec 25.

32.

Adiponectin: a risk biomarker and attractive target for chemoprevention.

Fabian CJ.

J Clin Oncol. 2012 Jan 10;30(2):124-6. doi: 10.1200/JCO.2011.38.5500. Epub 2011 Dec 12. No abstract available.

PMID:
22162567
33.

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K.

Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402.

34.

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators.

N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

35.

A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women.

Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, Nassif E, Brunner RL, Wood ME, Pater JL, Hu H, Qi S, Tu D, Goss PE.

Breast Cancer Res Treat. 2011 Apr;126(2):453-61. doi: 10.1007/s10549-010-1322-0. Epub 2011 Jan 9.

PMID:
21221773
36.

Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside.

Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, Sharma P, Setchell KD, Zhao X, Phillips TA, Metheny T, Hughes JR, Yeh HW, Johnson KA.

Cancer Prev Res (Phila). 2010 Oct;3(10):1342-50. doi: 10.1158/1940-6207.CAPR-10-0022. Epub 2010 Aug 19.

37.

How I treat vitamin d deficiency.

Khan QJ, Fabian CJ.

J Oncol Pract. 2010 Mar;6(2):97-101. doi: 10.1200/JOP.091087.

38.

The relationship between vitamin D and breast cancer incidence and natural history.

Khan QJ, Kimler BF, Fabian CJ.

Curr Oncol Rep. 2010 Mar;12(2):136-42. doi: 10.1007/s11912-010-0081-8. Review.

PMID:
20425599
39.

Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.

Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O'Dea AP, Klemp JR, Fabian CJ.

Breast Cancer Res Treat. 2010 Jan;119(1):111-8. doi: 10.1007/s10549-009-0495-x. Epub 2009 Aug 5.

40.

Surrogate response biomarkers in prevention research: do they point the way or lead us astray?

Fabian CJ.

J Clin Oncol. 2009 Aug 10;27(23):3734-6. doi: 10.1200/JCO.2009.22.9211. Epub 2009 Jul 13. No abstract available.

PMID:
19597020
41.

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL.

J Clin Oncol. 2009 Jun 20;27(18):2954-61. doi: 10.1200/JCO.2008.17.7618. Epub 2009 Apr 6.

PMID:
19349550
42.

Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.

Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM, Hartmann LC, Holland R, Winchester DJ; Consensus Conference Committee, Anderson BO, Arun BK, Bartelink H, Bernard P, Bonanni B, Cady B, Clough KB, Feig SA, Heywang-Köbrunner SH, Howell A, Isaacs C, Kopans DB, Mansel RE, Masood S, Palazzo JP, Pressman PI, Solin LJ, Untch M.

Breast J. 2009 Jan-Feb;15(1):4-16. doi: 10.1111/j.1524-4741.2008.00665.x.

43.

Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases.

Ting AY, Kimler BF, Fabian CJ, Petroff BK.

Cancer Prev Res (Phila). 2008 Dec;1(7):546-53. doi: 10.1158/1940-6207.CAPR-08-0015.

44.

Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.

Frank DH, Kimler BF, Fabian CJ, Ranger-Moore J, Yozwiak M, Bartels HG, Alberts DS, Bartels PH.

Breast Cancer Res Treat. 2009 Jun;115(3):661-8. doi: 10.1007/s10549-008-0274-0. Epub 2009 Jan 6.

PMID:
19125322
45.

Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.

Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM, Hartmann LC, Holland R, Winchester DJ; Consensus Conference Committee The International Consensus Conference Committee.

Cancer. 2008 Nov 15;113(10):2627-37. doi: 10.1002/cncr.23903.

46.

Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF.

Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC Jr, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6834-41.

47.

The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.

Fabian CJ.

Int J Clin Pract. 2007 Dec;61(12):2051-63. Epub 2007 Sep 24. Review.

48.

Low-dose tamoxifen for combination hormone replacement therapy users.

Fabian CJ.

J Clin Oncol. 2007 Sep 20;25(27):4162-4. Epub 2007 Aug 20. No abstract available.

PMID:
17709795
49.

Is there a future for ductal lavage?

Fabian CJ.

Clin Cancer Res. 2007 Aug 15;13(16):4655-6. No abstract available.

50.

Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.

PMID:
17655039

Supplemental Content

Loading ...
Support Center